You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. The Bumps: A Device for Rapid, Non-Invasive Quantification of Touch Sensation

    SBC: Neuro Devices, Inc.            Topic: 100

    The Bumps: A Device for Rapid, Non-Invasive Quantification of Touch Sensation Abstract !Our proposal describes an elegant device called the Bumps that quantifies finger pad touch sensation at low micron levels. The objectives are to diagnose peripheral neuropathy near its onset, when the possibility for reversal is highest, and to monitor either progression or reversal of neuropathy during treatme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Development of a Highly Specific Dengue Diagnostic Test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Cervical Spine Health Improvement Products

    SBC: Switchbox, Inc.            Topic: DHA18B001

    Most standard-of-care tools and techniques for evaluating neck disorders are subjective, unreliable, and do not provide actionable information for providers, payers, and organizations to deliver efficient and effective care. This lack of objective neck he

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  5. 3D Printed Multifunctional Brain Windows for Simultaneous Optical Imaging and Electrophysiology

    SBC: Applied Universal Dynamics, Corp.            Topic: 107

    PROJECT SUMMARY This proposal responds to PAR-18-870 titled “BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR).” This project is a Fast Track STTR with a phase I and phase II. The small business, Applied Universal Dynamics Corp. (AUD) is collaborating with the University of Minnesota (U of MN). The activity patterns of t ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems

    SBC: Prentke Romich Company            Topic: NIDCD

    Compatibility between Brain-Computer Interface and High Efficiency Augmentative and AlternativeCommunication Systems: Phase II ABSTRACT Brain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies

    SBC: CORNERSTONE RESEARCH GROUP INC            Topic: 101

    Project SummaryUltrasonic vocalizations (USVs) are known to reflect emotional processing, brain neurochemistry and brain function - key observations in animal model studies. Collecting and processing USV data is time-intensive, manual, and costly. Most importantly, it limits researchers’ ability to employ fully effective, and nuanced experimental designs, and is a barrier to entry for other rese ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. POC Blood Coagulopathy Monitor

    SBC: CFD RESEARCH CORP            Topic: DHA19A001

    Traumatic injuries account for 30% of all life years lost in the US and is the leading cause of death for people under 46 years of age. Uncontrolled bleeding or hemorrhage constitute 30-40% of trauma related deaths and are considered to be a major cause o

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  10. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government